Efficacy and Safety of MitoQ in Improving Cancer Cachexia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe First Affiliated Hospital of Xinxiang Medical College
About this trial
Muscle strength was evaluated in subjects with malignant solid tumors and cachexia after 12 weeks of oral MitoQ treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
MitoQ (mitoquinol mesylate)
Dietary supplementMitoQ 20 mg/day (one 20 mg capsule), administered orally once daily in the morning on an empty stomach.
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: MITOQ groupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
To evaluate the preliminary efficacy of MitoQ in patients with cancer cachexia
To evaluate the preliminary efficacy of MitoQ in patients with cancer cachexia by comparing muscle function before and after MitoQ administration at Weeks 13, as assessed by handgrip strength.
Time frame
0-13 WeeksSecondary outcomes
1
Inflammatory and Metabolic Markers
Changes in the levels of C-reactive protein (CRP).
Time frame
0-13 Weeks2
Clinical Benefit Endpoints
Changes in skeletal muscle mass at Weeks 13, as measured by the skeletal muscle index (SMI) at the third lumbar vertebra (L3) level using computed tomography (CT).
Time frame
0-13 Weeks3
Clinical Benefit Endpoints
Quality of life and symptom assessment using validated instruments: the EORTC QLQ-C30 (quality of life).
Time frame
0-13 weeksLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
The First Affiliated Hospital of Xinxiang Medical College
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: